Acrivon Therapeutics, Inc. financial data

Symbol
ACRV on Nasdaq
Industry
Pharmaceutical Preparations
Location
480 Arsenal Way, Suite 100, Watertown, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.32K % -30.5%
Debt-to-equity 9.78 % +0.83%
Return On Equity -47.3 % -14.7%
Return On Assets -43.1 % -44.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 31M shares +40.3%
Common Stock, Shares, Outstanding 31M shares +40.3%
Entity Public Float 158M USD
Common Stock, Value, Issued 31K USD +40.9%
Weighted Average Number of Shares Outstanding, Basic 36.1M shares +64.5%
Weighted Average Number of Shares Outstanding, Diluted 36.1M shares +64.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 15M USD +42.8%
General and Administrative Expense 6.41M USD +28.3%
Operating Income (Loss) -76.3M USD -54.3%
Nonoperating Income (Expense) 2.64M USD +64.3%
Net Income (Loss) Attributable to Parent -69M USD -54%
Earnings Per Share, Basic -2.78 USD/shares -98.6%
Earnings Per Share, Diluted -2.78 USD/shares -98.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 46M USD +20.8%
Assets, Current 182M USD +19%
Property, Plant and Equipment, Net 3.47M USD +75.5%
Operating Lease, Right-of-Use Asset 3.98M USD -9.31%
Assets 231M USD +44.1%
Accounts Payable, Current 1.26M USD -0.47%
Liabilities, Current 11.3M USD +60.8%
Operating Lease, Liability, Noncurrent 3.24M USD -15.7%
Liabilities 14.5M USD +33.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -19K USD +95.6%
Retained Earnings (Accumulated Deficit) -152M USD -83.4%
Stockholders' Equity Attributable to Parent 216M USD +44.8%
Liabilities and Equity 231M USD +44.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -17.1M USD -50.4%
Net Cash Provided by (Used in) Financing Activities -172K USD
Net Cash Provided by (Used in) Investing Activities 5.85M USD -37.3%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 31M shares +40.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -11.4M USD -462%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 46.4M USD +20.6%
Deferred Tax Assets, Valuation Allowance 31.8M USD +118%
Deferred Tax Assets, Gross 33.3M USD +104%
Operating Lease, Liability 4.22M USD -8.26%
Depreciation 735K USD +65.5%
Payments to Acquire Property, Plant, and Equipment 815K USD +3160%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -68.6M USD -30.6%
Lessee, Operating Lease, Liability, to be Paid 4.88M USD -11.8%
Property, Plant and Equipment, Gross 4.88M USD +84%
Operating Lease, Liability, Current 978K USD +29.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.34M USD +18.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.31M USD +18.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 662K USD -29.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.2M USD +3%
Deferred Tax Assets, Operating Loss Carryforwards 9.4M USD +53.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 404K USD -66.3%
Operating Lease, Payments 300K USD 0%
Additional Paid in Capital 368M USD +58.3%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.53M USD -14.5%
Share-based Payment Arrangement, Expense 13.2M USD +82.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%